Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT1VOHK)

• DTT Name: Potassium channel unspecific (KC) DTT Info
• Gene Name: KC

Molecule-Related Drug & Molecule List

10 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amifampridine	DMK08L3	LambertEaton myasthenic syndrome	8C62	Approved	[1]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[2]
Dalfampridine	DMM0PDO	Multiple sclerosis	8A40	Approved	[3]
Diazoxide	DML1538	Congenital hyperinsulinism	5A4Y	Approved	[2]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[2]
Dronedarone	DMA8FS5	Angina pectoris	BA40	Approved	[4]
Ibutilide	DMKXY2R	Atrial fibrillation	BC81.3	Approved	[2]
Minoxidil	DMA2Z4F	Alopecia	ED70	Approved	[2]
Nateglinide	DMLK2QH	Diabetic complication	5A2Y	Approved	[2]
Pinacidil	DMRADYL	High blood pressure	BA00	Approved	[2]

16 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Andolast	DMX36BH	Rhinitis	FA20	Phase 3	[5]
Azimilide	DMUIBV8	Atrial fibrillation	BC81.3	Phase 3	[6]
ATI-2042	DMWP59B	Atrial fibrillation	BC81.3	Phase 2	[7]
AZD-7009	DMIBXK0	Atrial fibrillation	BC81.3	Phase 2	[8]
Bimakalim	DMBRL19	Angina pectoris	BA40	Phase 2	[9]
HBI-3000	DM74ZKN	Heart arrhythmia	BC65	Phase 2	[10]
K-201	DMZCVD7	Atopic dermatitis	EA80	Phase 2	[11]
MSH-1001	DMUM370	Ocular hypertension	9C61.01	Phase 2	[12]
RP-49356	DM4N6PF	Hypertension	BA00-BA04	Phase 2	[13]
YM-934	DM7KR4C	Angina pectoris	BA40	Phase 2	[14]
AVE0118	DMSR91U	Obstructive sleep apnea	7A41	Phase 1	[15]
CLP-1004	DM2QBMI	Hypertension	BA00-BA04	Phase 1	[16]
Iptakalim	DMHW1LI	Hypertension	BA00-BA04	Phase 1	[17]
Nibentan	DM8J3WE	Cardiac arrhythmias	BC9Z	Phase 1	[18]
NS-8	DMX8LY4	Urinary incontinence	MF50.2	Phase 1	[19]
UK-66914	DMO8Z1D	Cardiac arrhythmias	BC9Z	Phase 1	[20]

46 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Levcromakalim	DMNS4TK	Chronic obstructive pulmonary disease	CA22	Discontinued in Preregistration	[21]
Acecainide	DMKM543	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 3	[22]
Alinidine	DMV2Y6L	Angina pectoris	BA40	Discontinued in Phase 3	[23]
Almokalant	DMV3PEA	Cardiac arrhythmias	BC9Z	Discontinued in Phase 3	[24]
BMS-204352	DMFZNLH	Nerve injury	ND56.4	Discontinued in Phase 3	[25]
Ambasilide	DMA57O4	Cardiac arrhythmias	BC9Z	Discontinued in Phase 2	[26]
BMS-180448	DMVBGIT	Angina pectoris	BA40	Discontinued in Phase 2	[27]
BRL-32872A	DMRKBIU	Cardiac arrhythmias	BC9Z	Discontinued in Phase 2	[28]
BRL-55834	DM0WG4U	Chronic obstructive pulmonary disease	CA22	Discontinued in Phase 2	[29]
E-4031	DMU872N	Cardiac arrhythmias	BC9Z	Discontinued in Phase 2	[30]
JTV-506	DMM8UNL	Angina pectoris	BA40	Discontinued in Phase 2	[31]
KCO-912	DMC30N4	Chronic obstructive pulmonary disease	CA22	Discontinued in Phase 2	[32]
KW-7158	DMJNSML	Urinary incontinence	MF50.2	Discontinued in Phase 2	[33]
P-1075	DM02ANM	Hypertension	BA00-BA04	Discontinued in Phase 2	[34]
Risotilide	DMNRGB7	Heart arrhythmia	BC65	Discontinued in Phase 2	[35]
Y-27152	DMO90RN	Angina pectoris	BA40	Discontinued in Phase 2	[36]
ZD-0947	DMS95DX	Overactive bladder	GC50.0	Discontinued in Phase 2	[37]
ZD-6169	DMVBL25	Urinary incontinence	MF50.2	Discontinued in Phase 2	[37]
Emakalim	DM2V5XP	Angina pectoris	BA40	Discontinued in Phase 1	[38]
KR-30450	DMMD6LR	Hypertension	BA00-BA04	Discontinued in Phase 1	[39]
NTC-801	DM1QZKS	Atrial fibrillation	BC81.3	Discontinued in Phase 1	[40]
Rilmakalim	DMBQZTO	Chronic obstructive pulmonary disease	CA22	Discontinued in Phase 1	[41]
Ro-31-6930	DMAJDPN	Hypertension	BA00-BA04	Discontinued in Phase 1	[42]
SDZ-PCO-400	DMZHOYM	Asthma	CA23	Discontinued in Phase 1	[43]
SR-47063	DMAICVN	Cardiac arrhythmias	BC9Z	Discontinued in Phase 1	[44]
Symakalim	DMSPBJ9	Hypertension	BA00-BA04	Discontinued in Phase 1	[45]
AL-0671	DMRYJ40	Arteriosclerosis	BD40	Terminated	[46]
AWD-23-111	DMD8ZM1	Heart arrhythmia	BC65	Terminated	[47]
E-4080	DMZ1JKX	Angina pectoris	BA40	Terminated	[48]
ICI-181037	DM0XU4P	Heart arrhythmia	BC65	Terminated	[49]
KC-399	DMD0FNH	Alopecia	ED70	Terminated	[50]
Ki-1769	DMQXPJB	Hypertension	BA00-BA04	Terminated	[51]
NS-004	DMCHLJ4	Hypertension	BA00-BA04	Terminated	[52]
NS-1546	DM75DZ1	Major depressive disorder	6A70.3	Terminated	[53]
NS-1608	DMYV9M1	Cerebrovascular ischaemia	8B1Z	Terminated	[54]
Org-20781	DM95QG2	Heart arrhythmia	BC65	Terminated	[55]
RP-66784	DM2GV78	Angina pectoris	BA40	Terminated	[56]
S-1389	DMDQGFR	Heart arrhythmia	BC65	Terminated	[57]
SB-237376	DMBCANZ	Arrhythmia	BC9Z	Terminated	[58]
TCV-295	DMCFGS6	Hypertension	BA00-BA04	Terminated	[59]
TERIKALANT	DM2X5R6	Cardiac arrhythmias	BC9Z	Terminated	[60]
UR-8225	DMJC82N	Asthma	CA23	Terminated	[61]
UR-8308	DM6C7WJ	Asthma	CA23	Terminated	[62]
UR-8328	DM4KOTA	Asthma	CA23	Terminated	[63]
WAY-123223	DMMOS8G	Heart arrhythmia	BC65	Terminated	[64]
YM-099	DMDXLG2	Hypertension	BA00-BA04	Terminated	[65]

8 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CGS-7181	DMZKS6Q	Discovery agent	N.A.	Investigative	[66]
HMR1883	DMNXR17	Discovery agent	N.A.	Investigative	[67]
L 691121	DMB73Y4	Discovery agent	N.A.	Investigative	[68]
MJ-451	DMMP6YH	Discovery agent	N.A.	Investigative	[69]
RP-66471	DMR4O3I	Discovery agent	N.A.	Investigative	[70]
Trecetilide fumarate	DME94KO	Cardiac arrhythmias	BC9Z	Investigative	[71]
WAY-125971	DMCSZG0	Discovery agent	N.A.	Investigative	[64]
Y-26763	DMZKPSQ	Discovery agent	N.A.	Investigative	[72]

References

• [1] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [3] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [4] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [5] BK channel modulators: a comprehensive overview. Curr Med Chem. 2008;15(11):1126-46.
• [6] Azimilide. Drugs. 2000 Feb;59(2):271-7; discussion 278-9.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Rapid slowing of the atrial fibrillatory rate after administration of AZD7009 predicts conversion of atrial fibrillation. J Electrocardiol. 2014 May-Jun;47(3):316-23.
• [9] Lack of anti-ischemic efficacy of the potassium channel opener bimakalim in patients with stable angina pectoris. Cardiovasc Drugs Ther. 2004 Jan;18(1):37-46.
• [10] Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85.
• [11] Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy
• [12] KR-31378, a potassium-channel opener, induces the protection of retinal ganglion cells in rat retinal ischemic models. J Pharmacol Sci. 2009 Apr;109(4):511-7.
• [13] Effects of pinacidil, RP 49356 and nicorandil on ATP-sensitive potassium channels in insulin-secreting cells. Br J Pharmacol. 1990 Mar;99(3):487-92.
• [14] Potassium channel opener, YM 934, inhibits neurogenic plasma leakage in guinea pig airways. Am J Respir Crit Care Med. 1994 Nov;150(5 Pt 1):1379-83.
• [15] Neurogenic contraction induced by the antiarrhythmic compound, AVE 0118, in rat small mesenteric arteries.Basic Clin Pharmacol Toxicol.2014 Oct;115(4):315-20.
• [16] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036783)
• [17] Iptakalim: A novel multi-utility potassium channel opener. J Pharmacol Pharmacother. 2012 Jan;3(1):12-4.
• [18] Nibentan -- a drug for pharmacological cardioversion of persistent atrial fibrillation. Kardiologiia. 2005;45(3):19-23.
• [19] Stimulation of large-conductance calcium-activated potassium channels inhibits neurogenic contraction of human bladder from patients with urinary symptoms and reverses acetic acid-induced bladder hyperactivity in rats. Eur J Pharmacol. 2014 Jul 15;735:68-76.
• [20] Electrophysiologic properties of UK-66,914, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol. 1991 Mar;17(3):376-85.
• [21] The potassium channel opener levcromakalim causes expansive remodelling of experimental vein grafts. J Vasc Surg. 2006 Jul;44(1):159-65.
• [22] Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias. Drugs. 1990 May;39(5):720-40.
• [23] Decrease in bradycardic effect of AQ-A 39 and alinidine in guinea-pig sinoatrial node depolarized by high external K+-concentration. Naunyn Schmiedebergs Arch Pharmacol. 1984 Dec;328(2):210-3.
• [24] Effect of almokalant, a selective potassium channel blocker, on the termination and inducibility of paroxysmal supraventricular tachycardias: a study in patients with Wolff-Parkinson-White syndrome and atrioventricular nodal reentrant tachycardia.Almokalant PSVT Study Group.J Cardiovasc Pharmacol.1995 Aug;26(2):198-206.
• [25] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [26] Ambasilide prolongs the action potential and blocks multiple potassium currents in human atrium. J Cardiovasc Pharmacol. 1999 May;33(5):762-71.
• [27] The novel cardioprotective agent BMS-180448 activates a potassium conductance in cardiac and vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol. 1996 Oct;354(4):444-51.
• [28] Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile... J Pharmacol Exp Ther. 1996 Feb;276(2):637-46.
• [29] Comparison of the airways relaxant and hypotensive potencies of the potassium channel activators BRL 55834 and levcromakalim (BRL 38227) in vivo in guinea-pigs and rats. Br J Pharmacol. 1993 Aug;109(4):1133-9.
• [30] Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes.Br J Pharmacol.2012 Jan;165(2):467-78.
• [31] Effects of the new potassium channel opener JTV-506 on coronary vessels in vitro and in vivo. Arzneimittelforschung. 1999 Mar;49(3):199-206.
• [32] KCO912: a potent and selective opener of ATP-dependent potassium (K(ATP)) channels which suppresses airways hyperreactivity at doses devoid of card... Naunyn Schmiedebergs Arch Pharmacol. 2002 Mar;365(3):220-30.
• [33] KW-7158 [(2S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide] enhances A-type K+... J Pharmacol Exp Ther. 2004 Jul;310(1):159-68.
• [34] The effects of potassium channel opener P1075 on the human saphenous vein and human internal mammary artery. J Cardiovasc Pharmacol. 2011 Jun;57(6):648-55.
• [35] Electrophysiological effects of left ventricular hypertrophy. Effect of calcium and potassium channel blockade. Circulation. 1991 Jun;83(6):2067-75.
• [36] Pharmacokinetics and safety of a novel, long-acting, prodrug-type potassium channel opener, Y-27152, in healthy volunteers. J Clin Pharmacol. 1996 May;36(5):439-51.
• [37] Effects of ZD6169 and ZD0947, 2 potassium adenosine triphosphate channel openers, on bladder function of spinalized rats. J Urol. 2002 Aug;168(2):837-42.
• [38] Therapeutic potential of potassium channel activators in coronary heart disease. Eur Heart J. 1994 Aug;15 Suppl C:82-8.
• [39] Cardioprotective effects of KR-30450, a novel K+(ATP) opener, and its major metabolite KR-30818 on isolated rat hearts. Jpn J Pharmacol. 1998 Jan;76(1):65-73.
• [40] Effects of the selective KACh channel blocker NTC-801 on atrial fibrillation in a canine model of atrial tachypacing: comparison with class Ic and III drugs. J Cardiovasc Pharmacol. 2014 May;63(5):421-7.
• [41] Hypotonic stress increases efficacy of rilmakalim, but not pinacidil, to activate ATP-sensitive K(+) current in guinea pig ventricular myocytes. J Pharmacol Sci. 2004 Jun;95(2):189-95.
• [42] Evaluation of the bronchodilator properties of Ro 31-6930, a novel potassium channel opener, in the guinea-pig. Br J Pharmacol. 1990 Jun;100(2):289-94.
• [43] Effects of a potassium channel opener (SDZ PCO 400) on guinea-pig and human pulmonary airways. Br J Pharmacol. 1992 Jun;106(2):423-9.
• [44] Vasorelaxant effects of the potassium channel opener SR 47063 on the isolated human saphenous vein and rat aorta. Braz J Med Biol Res. 2000 Aug;33(8):961-6.
• [45] Synthesis and antihypertensive activity of 4-(diazabicyclo[4.1.0]-heptenyloxy)benzopyran derivatives and their analogues. Chem Pharm Bull (Tokyo). 1998 Apr;46(4):602-9.
• [46] A possible mechanism of action of a new potassium channel opener, AL0671, on lipid metabolism in obese Zucker rats. J Pharmacol Exp Ther. 1994 Dec;271(3):1666-71.
• [47] The new antiarrhythmic substance AWD 23-111 inhibits the delayed rectifier potassium current (IK) in guinea pig ventricular myocytes. Pharmazie. 1999 Jan;54(1):61-8.
• [48] Ionic currents involved in vasodilating actions of E4080, a newly synthesized bradycardia-inducing agent, in dispersed smooth muscle cells of the rabbit portal vein. J Pharmacol Exp Ther. 1991 Dec;259(3):1396-403.
• [49] ICI 181,037: a novel eukalemic diuretic with antiarrhythmic activity. Jpn J Pharmacol. 1991 Nov;57(3):263-77.
• [50] Action of KC-399, a newly synthesized potassium channel opener, on mechanical activity and 86Rb efflux in rat aorta. J Cardiovasc Pharmacol. 1994 Feb;23(2):220-6.
• [51] Vasorelaxant action of Ki1769, a new pyridinecarboximidamide, in isolated porcine coronary artery. Eur J Pharmacol. 1993 Sep 14;241(2-3):177-81.
• [52] Effects of K+ channel inhibitors and antagonists on NS-004 evoked relaxations in guinea-pig isolated trachea. Fundam Clin Pharmacol. 1997;11(1):78-82.
• [53] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006187)
• [54] Modulation of the Ca(2+)-dependent K+ channel, hslo, by the substituted diphenylurea NS 1608, paxilline and internal Ca2+. Neuropharmacology. 1996;35(7):903-14.
• [55] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003350)
• [56] Syntheses and biological activities of potent potassium channel openers derived from (+/-)-2-oxo-1-pyridin-3-yl-cyclohexanecarbothioic acid methylamide: new potassium channel openers. J Med Chem. 1993 May 28;36(11):1604-12.
• [57] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000214)
• [58] Electrophysiologic effects of SB-237376: a new antiarrhythmic compound with dual potassium and calcium channel blocking action. J Cardiovasc Pharmacol. 2003 Mar;41(3):414-21.
• [59] Antihypertensive and cardiovascular effects of a new potassium channel opener, TCV-295, in rats and dogs. J Cardiovasc Pharmacol. 1994 Dec;24(6):929-36.
• [60] Terikalant, an inward-rectifier potassium channel blocker, does not abolish the cardioprotection induced by ischemic preconditioning in the rat. J Mol Cell Cardiol. 1998 Sep;30(9):1817-25.
• [61] Effects of the novel potassium channel opener, UR-8225, on contractile responses in rat isolated smooth muscle. Br J Pharmacol. 1993 Nov;110(3):1165-71.
• [62] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005294)
• [63] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005293)
• [64] Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives. J Med Chem. 1991 Nov;34(11):3212-28.
• [65] Potassium channel-opening and vasorelaxant profiles of a novel compound YM099 in rat isolated portal vein and rabbit isolated aorta. Arch Int Pharmacodyn Ther. 1994 May-Jun;327(3):330-43.
• [66] Molecular mechanism of pharmacological activation of BK channels
• [67] Clamikalant (Aventis). IDrugs. 2000 Nov;3(11):1353-7.
• [68] Embryotoxic effects of L-691,121, a class III antiarrhythmic agent, in rats. Arch Toxicol. 1994;69(1):65-71.
• [69] Pharmacological characteristics of MJ-451, a new benzopyran- derived ATP-sensitive potassium channel opener, in guinea pig isolated trachea. Pharmacology. 1998 Dec;57(6):314-22.
• [70] Potassium channel opener, RP 66471, induces membrane depolarization of rat liver mitochondria. Biochem Biophys Res Commun. 1995 Feb 6;207(1):126-32.
• [71] IKr channel blockers: novel antiarrhythmic agents. Curr Med Chem Cardiovasc Hematol Agents. 2003 Oct;1(3):203-23.
• [72] Y-26763: ATP-sensitive K+ channel activation and the inhibition of insulin release from human pancreatic beta-cells. Eur J Pharmacol. 2004 Feb 20;486(2):133-9.